Inflammatory Bowel Disease in Renal Transplant Recipients: A Retrospective Multicenter Study
Nephrology, Bretonneau Hospital, Tours, France
Nephrology, Maison Blanche Hospital, Reims, France
Nephrology, Bois Guillaume Hospital, Rouen, France
Nephrology, Côte de Nacre Hospital, Caen, France
Nephrology, La Cavale Blanche Hospital, Brest, France
Nephrology, Dupuytren Hospital, Limoges, France
Nephrology, Nouvel Hôpital Civil, Strasbourg, France
Nephrology, Gabriel Montpied Hospital, Clermont-Ferrand, France
Nephrology, Necker Hospital, Paris, France
Nephrology, La Milétrie Hospital, Poitiers, France
Nephrology, Georges Pompidou European Hospital, Paris, France
Nephrology, Pontchaillou Hospital, Rennes, France
Meeting: 2013 American Transplant Congress
Abstract number: C1378
Inflammatory bowel disease (IBD) can occur before or, despite corticoids and immunosuppressive treatment, after transplantation. We collected characteristics of cases of IBD in renal transplant recipients in order to determine factors associated with flare-up of IBD after transplantation.
This is a retrospective multicenter study including 12 French transplant centers. We included all renal transplanted recipients with IBD before or after transplantation separated into 3 groups: IBD before transplantation without recurrence (no recurrent IBD), IBD before transplantation with recurrence post-transplantation (recurrent IBD) and IBD developed after transplantation without IBD before transplantation (de novo IBD). Demographic characteristics, history of auto-immune disease (AID), IBD evolution before and after transplantation, CMV infection and immunosuppressive treatment were recorded.
We included 40 patients (no recurrent IBD= 17; recurrent IBD =11 and de novo IBD=12). All but one patient received an induction therapy (19 polyclonal antibodies and 20 anti-IL2R). Mean age at transplantation for all patients was 40.6±12,7 years with 26% of men. The median delay of flare-up after transplantation was 17 (1-167) months in the recurrent IBD group and 91 (3-139) months in the de novo IBD group. CMV infection was significantly more frequent in patients who recurred (4/11) compared to patients who did not reccur (1/17). We did not observe any correlation between pre-existing AID or the immunosuppressive treatment and IBD before or after transplantation.
We report the most extensive cohort of IBD in renal transplant recipients. CMV infection may trigger recurrence of IBD after transplantation.
To cite this abstract in AMA style:
Fournier A, Barbet C, Toupance O, Etienne I, Ligny BHuraultde, Lemeur Y, Rerolle J, Ohlmann S, Tiple A, Anglicheau D, Touchard G, Thervet E, Rivalan J, Lebranchu Y, Büchler M. Inflammatory Bowel Disease in Renal Transplant Recipients: A Retrospective Multicenter Study [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/inflammatory-bowel-disease-in-renal-transplant-recipients-a-retrospective-multicenter-study/. Accessed December 2, 2024.« Back to 2013 American Transplant Congress